HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation

BACKGROUND: The introduction of direct-acting antivirals (DAA) for HCV has led to high rates of HCV eradication. Treatment of patients awaiting liver transplantation (LT) has been controversial. Recent data suggests that DAA treatment may accelerate recurrent HCC. The impact of DAA on delisting for...

Descripción completa

Detalles Bibliográficos
Autores principales: Emamaullee, Juliet A., Bral, Mariusz, Meeberg, Glenda, Montano-Loza, Aldo J., Bain, Vincent G., Burak, Kelly Warren, Bigam, David, Shapiro, A. M. James, Kneteman, Norman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354133/
https://www.ncbi.nlm.nih.gov/pubmed/30775356
http://dx.doi.org/10.1155/2019/2509059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354133/
https://www.ncbi.nlm.nih.gov/pubmed/30775356
http://dx.doi.org/10.1155/2019/2509059

Ejemplares similares